AlphAIAlphAI — Financial news for AI agents
fool.com$HUM

Humana (HUM) Q3 2026 Earnings Call Transcript

Humana (HUM) reported Q3 2026 earnings with adjusted EPS of $17.17 YTD and a Q3 loss of $0.70, down from $3.24 YoY. Full-year adjusted EPS guidance raised to at least $9.50. GAAP EPS for Q3 was $1.33, down from $1.62 in 2025. The company expects $900M in pretax proceeds from Gentiva divestment. Medicare Advantage enrollment and Star ratings improved, but Part D cost trends are expected to rise to 14-15% in 2027.

Original reporting
fool.com
Published Nov 6, 2026, 6:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 6:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Humana (HUM) Q3 2026 Earnings Call Transcript — source image
Source · fool.com
Decision brief

The 30-second read

$HUMBullishHigh
01

Why it matters

The upward guidance revision is a fresh, material development that can shift investor sentiment and price action.

02

Market read

Guidance lift is a primary earnings catalyst for HUM and may influence the broader health‑insurance sector.

03

What to watch

Potential headwinds from rising Part D drug costs and Star‑rating pressures could temper upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Humana's Q3 2026 earnings call provided updated financial metrics and forward guidance.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

Humana raised its full‑year 2026 adjusted EPS guidance to at least $9.50 from $9.00 and GAAP EPS guidance to at least $15.09, a material upward revision disclosed for the first time.

Expected impact

likely upside as investors price in higher earnings expectations

Evidence & confidence

Guidance revisions are primary earnings news for a large‑cap insurer; the magnitude and direction are clear.

Market effects

Sector

Higher guidance may lift other health‑insurance peers as investors reassess sector earnings outlook.

Regional

U.S. health‑care index could see modest gains.

Global

Limited; primarily U.S. market focus.

Counterpoint

What could challenge this read

If the guidance upgrade is already priced in, the stock could face a short‑term pull‑back.

Key entities

  • Executive
    James Rechtin

    President and CEO of Humana

  • Executive
    Celeste Mellet

    Chief Financial Officer of Humana

Read at source← All news

StoryHumana reports third-quarter loss and raises 2026 adjusted EPS guidance

Also covered by

6 outlets

Related articles

$HUMHighAI 8/10

Humana 3Q 2026: Revenue $41.16B, EPS $1.33 — 10-Q Summary

Humana reported 3Q 2026 revenue of $41.16B, up 26.1% YoY, driven by Medicare membership growth and higher premiums. Net income fell 16.9% to $162M, with EPS at $1.33. Insurance membership grew 20.3%, but the segment saw a $303M operating loss. CenterWell revenue rose 40.4% to $1.9B, though costs increased.

tradingview.com
$HUMMedAI 8/10

Humana Inc. Q3 2026 Earnings Call Summary

Humana Inc. raised its 2026 adjusted EPS outlook due to strong operational performance and medical cost trends. The company is focusing on top quartile Star ratings and expects 2027 membership growth. A joint venture with BlackRock aims to improve balance sheet efficiency. Humana anticipates a 3%+ individual MA margin by 2028, with 2027 showing progress. The divestment of Gentiva is expected to close in Q4 2026, providing $900 million in pretax proceeds.

finance.yahoo.com
$HUMHighAI 8/10

Humana Raises Profit Floor on Lower Costs

Humana (HUM) raised its 2026 adjusted earnings guidance to at least $9.50 per share from $9.00, citing lower costs. Q3 insurance benefit ratio was 93.7%, better than expected. Shares fell 0.59% in pre-market trading. Humana's Medicare Advantage membership grew 23% this year.

asktraders.com
$HUMHighAI 8/10

HUM Q3 FY2026 earnings call

Humana Inc. reported Q3 2026 earnings exceeding expectations, raising full-year adjusted EPS guidance to at least $9.50. The company cited favorable medical cost trends and strong execution. Management highlighted progress in clinical quality, Medicaid expansion, and capital allocation, including a divestiture and a new joint venture. Humana expects 2027 Medicare Advantage membership growth and an 8%-9% medical cost trend, with risks and opportunities outlined.

finance.biggo.com